News
Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today announced that it will attend the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback